Kineta Inc
Change company Symbol lookup
Select an option...
KA Kineta Inc
BNMV BitNile Metaverse Inc
FCF First Commonwealth Financial Corp
ARMN Aris Mining Corp
IBM International Business Machines Corp
JPM JPMorgan Chase & Co
GEHC GE Healthcare Technologies Inc
GE General Electric Co
PFE Pfizer Inc

Health Care : Biotechnology | Small Cap Growth
Company profile

Kineta, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing differentiated immunotherapies that address the challenges with current cancer therapy. Its innate immunity development platform aimed at developing human antibodies to address the mechanisms of cancer immune resistance, such as immuno-suppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of assets and research interests includes KVA12123, a monoclonal antibody (mAb), immunotherapy targeting V-domain Ig suppressor of T cell activation (VISTA), an anti-CD27 agonist mAb immunotherapy and an anti-CD24 antagonist mAb immunotherapy discovery program. VISTA blocks immunotherapy to address the problem of immunosuppression in the tumor microenvironment. It is developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells in the tumor microenvironment. KVA12123 are primarily focused on solid tumors with high levels of VISTA expression.

Day's Change
-0.6008 (-13.38%)
B/A Size
Day's High
Day's Low
(Heavy Day)

Today's volume of 262,057 shares is on pace to be much greater than KA's 10-day average volume of 38,484 shares.


Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.